Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2025 results on Oct. 30, after market close. In the last ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

Edwards Lifesciences Corp (EW) has reached a new 52-week high, with its stock price climbing to 83.02 USD. According to InvestingPro data, the company maintains strong financial health with a "GOOD" ...

A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against ...

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and ...